Skip to main content
. 2017 Apr 5;6(2):6. doi: 10.3390/antib6020006

Figure 2.

Figure 2

Distribution of levels of antibodies to CB10 at onset among 65 patients with early RA who had anti-CB10, grouped according to outcome—remission, persisting non-erosive arthritis or erosive arthritis.